clinical trial · NCT07437404
Efficacy and Safety Evaluation Study of SCT800 in Previously Untreated Hemophilia A Patients.
Sinocelltech Ltd.·phase3·recruiting·n = 36
Haemophilia ASCT800 prophylaxis and treatment for bleeding events
brief summary
This is an Open Label, Uncontrolled Study to Evaluate the the Safety and Efficacy of SCT800 for Prophylaxis Treatment in Severe Previously Untreated Hemophilia Patients.
started
Apr 26, 2024
primary completion
Dec 26, 2028
completion
Dec 26, 2028
last updated
Feb 27, 2026
detailed description
SCT800 is a recombinant human coagulation factor VIII, which was on market in 2021 in China. The indication of SCT800 is prophylaxis and control of bleeding events in adult and children, and for the perioperative management of bleeding events. This study continued to evaluate the safety and efficacy of SCT800 in previously untreated patients with severe haemophilia A.
official title
An Open Label, Uncontrolled Study to Evaluate the the Safety and Efficacy of SCT800 for Prophylaxis Treatment in Severe Previously Untreated Hemophilia Patients.
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol